Welcome to our dedicated page for RIGEL PHARMACEUTICALS SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.
The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock. The option was originally granted on January 29, 2025 with an exercise price of $22.49 per share.
The award carried a performance-based vesting condition and was not reportable until that metric was satisfied. On June 17, 2026, the company determined the performance metric had been met, and the option became fully vested, leaving Schorno with 7,394 option shares following the transaction.
Kamil Ali-Jackson reports a sale of 2,500 shares of common stock. The filing shows 2,500 shares were sold on 05/26/2026 for $72,925.00, with Fidelity Brokerage Services LLC listed as the broker. The securities were reported as vested restricted stock with a vesting date of 05/21/2024.
Rigel Pharmaceuticals, Inc. completed a major licensing transaction, making its License Agreement with Arvinas, Inc., Arvinas affiliates and Pfizer Inc. effective for VEPPANU™ (vepdegestrant). The deal grants Rigel exclusive, global rights to develop, manufacture and commercialize VEPPANU and related products worldwide.
Following early termination of the Hart-Scott-Rodino antitrust waiting period and satisfaction of closing conditions, Rigel closed the transaction and paid the licensors a one-time upfront payment of $70.0 million.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares. On June 1, 2026, he exercised options for 2,181 shares of common stock at $12.70 per share and 1,200 shares at $18.70 per share. To cover tax obligations, 928 shares of common stock were disposed of at a value of $29.86 per share, a tax-withholding transaction rather than an open-market sale. Following these transactions, he directly held 78,790 shares of Rigel common stock. The filing also notes all share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
RIGEL PHARMACEUTICALS INC executive David A. Santos, EVP and Chief Commercial Officer, reported a small share disposition related to taxes. On this date, 874 shares of common stock were delivered at $29.86 per share to cover tax obligations. After this tax-withholding event, Santos directly holds 61,996 shares of common stock, indicating that his overall ownership position remains largely unchanged.
RIGEL PHARMACEUTICALS INC EVP and Chief Medical Officer Lisa Rojkjaer reported a tax-related share disposition. On June 1, 2026, 850 shares of Common Stock were transferred at $29.86 per share to cover an exercise price or tax liability by delivering securities.
After this transaction, she directly owned 34,003 shares of Rigel common stock. The filing reflects a tax-withholding disposition rather than an open-market purchase or sale.
RIGEL PHARMACEUTICALS INC CEO and President Raul R. Rodriguez reported a Form 4 transaction involving a tax-related share disposition. On June 1, 2026, 2,424 shares of Common Stock were delivered at $29.86 per share to satisfy tax obligations. After this transaction, Rodriguez directly holds 279,593 shares of Common Stock, indicating the event reflects routine tax withholding rather than an open-market trade.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey reported a small tax-related share disposition. On June 1, 2026, 877 shares of common stock were delivered at $29.86 per share to cover tax obligations, a non‑market transaction classified as a tax-withholding disposition. Following this, he directly holds 50,936 common shares, indicating the adjustment is minor relative to his remaining position.
RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share. Following the sale, the director directly holds 12,625 shares. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.